Bendroflumetiazid
Bendroflumetiazid
Klass: A
Visa all info
Skriv ut
Kontakta oss
Produkter
Visa alla produkter
Bendroflumetiazid Alternova, Bendroflumetiazid Evolan, ......
Bendroflumetiazid Alternova, Bendroflumetiazid Evolan, SaluresATC-koder
C03AA01
C03AA01Substanser
bendroflumetiazid
bendroflumetiazidSammanfattning
En stor randomiserad, kontrollerad klinisk blodtrycksstudie med bendroflumetiazid visade en mortalitetssänkning hos män men inte hos kvinnor.
Risken för gikt och impotens har i en stor randomiserad studie visats vara vanligare för män behandlade med bendroflumetazid. I denna studie avbröt fler män än kvinnor behandling i studien, främst på grund av dessa biverkningar.
Background
Pharmacokinetics and dosing
Visa hela bakgrundstexten
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of bendroflumethiazide have been found.
Effects
The large Medical Research Council (MRC) trial of treatment of mild hypertension (7513 men, 6945 women) compared treatment with bendroflumethiazide and propranolol. Results showed a benefit associated with bendroflumethiazide treatment in men, but the opposite effect in women. All-cause mortality rates were: 7.5% deaths in bendroflumethiazide-treated men compared with 8.2% in placebo-treated men; 4.5% deaths in bendroflumethiazide-treated women compared with 3.5% on placebo [1].
Adverse effects
Adverse reactions to bendroflumethiazide were evaluated in a sub-analysis of theMRC treatment trial. Patients received 5 mg bendroflumethiazide twice daily. Men had significantly higher incidences of gout and of impotence, compared with controls. After 5 years, 17.1% of the men had been withdrawn from treatment with bendroflumethiazide compared with 12.8% of the women (p<0.05). The difference is mainly due to the higher i......
Försäljning på recept
Visa hela försäljning på recept
Fler kvinnor än män hämtade ut tabletter innehållande bendroflumetiazid (ATC-kod C03AA01) på recept i Sverige år 2018, totalt 57 303 kvinnor och 36 908 män. Det motsvarar 11 respektive 7 personer per tusen invånare. Andelen som hämtat ut läkemedel ökade med stigande ålder hos båda könen. I genomsnitt var tabletter innehållande bendroflumetiazid 1,4 gånger vanligare hos kvinnor [6].
Referenser
Visa referenser
MRC trial of treatment of mild hypertension: principal results Medical Research Council Working Party. Br Med J (Clin Res Ed). 1985;291:97-104.
Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet. 1991;2:539-543.
Ramsay LE, Boyle P, Ramsay MH. Factors influencing serum potassium in treated hypertension. Q J Med. 1977;46:401-10.
Toner JM, Ramsay LE. Thiazide-induced hypokalaemia; prevalence higher in women. Br J Clin Pharmacol. 1984;18:449-52.
Ahlstrand C, Tiselius HG, Larsson L, Hellgren E. Clinical experience with long-term bendroflumethiazide treatment in calcium oxalate stone formers. Br J Urol. 1984;56:255-62.
Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.]
- MRC trial of treatment of mild hypertension: principal results Medical Research Council Working Party. Br Med J (Clin Res Ed). 1985;291:97-104.
- Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet. 1991;2:539-543.
- Ramsay LE, Boyle P, Ramsay MH. Factors influencing serum potassium in treated hypertension. Q J Med. 1977;46:401-10.
- Toner JM, Ramsay LE. Thiazide-induced hypokalaemia; prevalence higher in women. Br J Clin Pharmacol. 1984;18:449-52.
- Ahlstrand C, Tiselius HG, Larsson L, Hellgren E. Clinical experience with long-term bendroflumethiazide treatment in calcium oxalate stone formers. Br J Urol. 1984;56:255-62.
- Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.]
Uppdaterat
Litteratursökningsdatum 5/2/2019
Litteratursökningsdatum 5/2/2019